Hôpital Beaujon

Futó vizsgálatok

• Még nem toboroz

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· 4. fázis· Assistance Publique Hopitaux De Marseille· Forrás

• Még nem toboroz

  Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  NCT07890012· Hospices Civils de Lyon· Forrás

• Még nem toboroz

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· 4. fázis· University Hospital, Clermont-Ferrand· Forrás

• Még nem toboroz

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Toboroz

  Peer Support in Alcohol Dependence

  NCT06381609· Hospices Civils de Lyon· Forrás

• Még nem toboroz

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Forrás

• Toboroz

  Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

  NCT07654283· 2. fázis· AusperBio Therapeutics Inc.· Forrás

• Toboroz

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás

• Toboroz

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· 3. fázis· Boehringer Ingelheim· Forrás

• Toboroz

  LEOPARD Prospective Validation Cohort 1

  NCT06723275· Assistance Publique - Hôpitaux de Paris· Forrás

• Toboroz

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Még nem toboroz

  Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial

  NCT07497750· University Hospital, Toulouse· Forrás

• Toboroz

  Multicenter Study for External Validation of the TB-NET Score

  NCT07903532· Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz· Forrás

• Toboroz

  Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

  NCT07585890· University Medical Center Groningen· Forrás

• Még nem toboroz

  Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

  NCT07337447· 2. fázis· Hospices Civils de Lyon· Forrás

• Toboroz

  Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors: a basket diagnostic performance study

  2024-519505-35-00· 3. fázis· Centre Hospitalier Universitaire De Nantes· Forrás

• Toboroz

  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

  NCT06254248· 2. fázis· Assistance Publique - Hôpitaux de Paris· Forrás

• Fut, nem toboroz

  Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.

  NCT03524352· 3. fázis· Centre Hospitalier Universitaire De Nantes· Forrás

• Toboroz

  Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

  NCT06990659· University Hospital, Angers· Forrás

• Toboroz

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· 3. fázis· GlaxoSmithKline· Forrás

• Toboroz

  Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

  NCT07044453· 2/3. fázis· University Hospital, Rouen· Forrás

• Toboroz

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects with Chronic Hepatitis B (B-SUPREME)

  2025-521178-33-00· 2. fázis· Aligos Therapeutics Inc.· Forrás

• Toboroz

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

  NCT06529718· 2. fázis· UNICANCER· Forrás

• Fut, nem toboroz

  A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection

  2025-521096-31-00· 3. fázis· Atea Pharmaceuticals Inc.· Forrás

• Toboroz

  [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.

  NCT06999837· 1/2. fázis· Nantes University Hospital· Forrás

• Toboroz

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· 2/3. fázis· Exelixis· Forrás

• Még nem toboroz

  A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

  NCT06984718· 2. fázis· Akeso· Forrás

• Még nem toboroz

  Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

  NCT06263816· 3. fázis· University Hospital, Tours· Forrás

• Toboroz

  Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  NCT06878664· 3. fázis· Grupo Espanol de Tumores Neuroendocrinos· Forrás

• Toboroz

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· 3. fázis· Novartis Pharmaceuticals· Forrás

• Toboroz

  MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER”

  2023-508201-25-00· 2. fázis· Centre De Lutte Contre Le Cancer Eugene Marquis· Forrás

• Toboroz

  Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

  NCT06551272· 2. fázis· Center Eugene Marquis· Forrás

• Toboroz

  Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension

  NCT06687265· 2. fázis· Assistance Publique - Hôpitaux de Paris· Forrás

• Toboroz

  LEOPARD Training and Validation Data Collection Study

  NCT06675604· Assistance Publique - Hôpitaux de Paris· Forrás

• Toboroz

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· 2. fázis· UNICANCER· Forrás

• Fut, nem toboroz

  Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

  NCT06501625· 1/2. fázis· Institut de Recherches Internationales Servier· Forrás

• Toboroz

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  2024-512895-36-00· 3. fázis· Akero Therapeutics Inc.· Forrás

• Toboroz

  Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

  NCT06680232· 1. fázis· Precision BioSciences, Inc.· Forrás

• Toboroz

  Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial

  2024-514633-38-00· 3. fázis· Centre Hospitalier Universitaire Amiens Picardie· Forrás

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

  NCT06427941· 1/2. fázis· BeOne Medicines· Forrás

• Toboroz

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· 3. fázis· Jazz Pharmaceuticals· Forrás

• Toboroz

  Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

  NCT06334965· Assistance Publique - Hôpitaux de Paris· Forrás

• Toboroz

  A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

  NCT05895136· 2. fázis· European Foundation for Study of Chronic Liver Failure· Forrás

• Toboroz

  A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

  2023-505660-11-00· 3. fázis· Transthera Sciences (Nanjing) Inc.· Forrás

• Toboroz

  Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

  NCT05300035· 2. fázis· ANRS, Emerging Infectious Diseases· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  NCT06318169· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  2023-505141-48-00· 3. fázis· Akero Therapeutics Inc.· Forrás

Showing 50 of 94.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Máj- és epeúti rák22 toboroz
• Neuroendokrin daganatok11 toboroz
• Hasnyálmirigyrák8 toboroz
• Liver cirrhosis6 toboroz
• Zsírmáj (MASLD/MASH)6 toboroz
• Hepatitis B (krónikus)4 toboroz
• Colitis ulcerosa3 toboroz
• Crohn-betegség3 toboroz
• Vastagbélrák3 toboroz
• Gyermekkori daganatok2 toboroz
• Magas vérnyomás2 toboroz
• Primer biliáris cholangitis (PBC)2 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• HIV-fertőzés1 toboroz
• Sarlósejtes vérszegénység1 toboroz
• Tüdőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

  NCT06855056· European Foundation for Study of Chronic Liver Failure· Forrás

• Lezárult

  A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

  2023-509027-41-00· 1. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Lezárult

  Open-Label Study of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab in Subjects with Chronic HBV Infection

  NCT06245291· 2. fázis· Arbutus Biopharma Inc.· Forrás

• Lezárult

  Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.

  NCT04777851· 3. fázis· Translational Research In Oncology· Forrás

• Lezárult

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· 2. fázis· Organon LLC· Forrás

• Fut, nem toboroz

  A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

  NCT06246643· 2. fázis· Bayer· Forrás

• Fut, nem toboroz

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

  NCT05612581· 1/2. fázis· Vir Biotechnology, Inc.· Forrás

• Lezárult

  Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

  NCT05665348· 2/3. fázis· Federation Francophone de Cancerologie Digestive· Forrás

• Lezárult

  Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)

  2024-511538-11-00· 2. fázis· Institut Gustave Roussy· Forrás

• Lezárult

  Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

  NCT05448677· 2. fázis· Centre Hospitalier Universitaire De Grenoble· Forrás

• Leállították

  Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

  NCT05516498· 2. fázis· AstraZeneca· Forrás

• Lezárult

  International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

  NCT05387811· Azienda Ospedaliera di Padova· Forrás

• Lezárult

  An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

  NCT05275023· 2. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

  NCT05123599· 1. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients

  NCT04802954· IHU Strasbourg· Forrás

• Lezárult

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· 3. fázis· AbbVie· Forrás

• Lezárult

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· 2. fázis· Gilead Sciences· Forrás

• Lezárult

  A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

  NCT04585789· 2. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

  NCT04567615· 2. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· 2. fázis· Bayer· Forrás

• Lezárult

  Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients

  NCT04335968· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás

• Lezárult

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Forrás

• Lezárult

  A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

  NCT04535544· 2. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

  NCT04439539· 2. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)

  NCT04483726· University Hospital, Montpellier· Forrás

• Lezárult

  A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  NCT04225715· 2. fázis· Hoffmann-La Roche· Forrás

• Lezárult

  A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

  NCT04039607· 3. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

  NCT03838263· 2. fázis· UNICANCER· Forrás

• Lezárult

  Microvesicles and Monocytes to Predict Mortality of Patients with Cirrhosis

  NCT03837444· Assistance Publique - Hôpitaux de Paris· Forrás

• Lezárult

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Leállították

  "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer"

  NCT03876561· Nantes University Hospital· Forrás

• Lezárult

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· 3. fázis· Kyntra Bio· Forrás

• Lezárult

  Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality

  NCT03702920· 3. fázis· Instituto Grifols S.A.· Forrás

• Lezárult

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Boston Scientific Corporation· Forrás

• Lezárult

  A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

  NCT03656536· 3. fázis· Incyte Corp.· Forrás

• Lezárult

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Fut, nem toboroz

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· 3. fázis· Eli Lilly and Company· Forrás

• Fut, nem toboroz

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· 3. fázis· AbbVie· Forrás

• Lezárult

  A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation

  2023-508726-10-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás

• Lezárult

  Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma

  NCT02799212· 3. fázis· Hospices Civils de Lyon· Forrás

• Lezárult

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· 3. fázis· BeiGene· Forrás

• Lezárult

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· 2. fázis· Hospices Civils de Lyon· Forrás

• Lezárult

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· 3. fázis· Alfasigma S.p.A.· Forrás

• Lezárult

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· 2. fázis· Institut de Cancérologie de Lorraine· Forrás

• Lezárult

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Forrás

• Lezárult

  Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy

  NCT02514278· 3. fázis· University Hospital, Bordeaux· Forrás

Showing 50 of 52.

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Máj- és epeúti rák102 munka · 54 vizsgálat
• Zsírmáj (MASLD/MASH)32 munka · 11 vizsgálat
• Neuroendokrin daganatok16 munka · 15 vizsgálat
• Hepatitis B (krónikus)9 munka · 13 vizsgálat
• Gaucher-kór3 munka · 0 vizsgálat